Are chimeric antigen receptor T cells ready for prime time?

Clinical Advances in Hematology and Oncology

Volumn 14, Issue 1, 2016, Pages 17-19

  Brentjens, Renier J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD40 LIGAND; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 12; PROSTATE SPECIFIC MEMBRANE ANTIGEN; T LYMPHOCYTE RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE SYNDROME; ECONOMIC ASPECT; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE RESPONSE; OUTCOME ASSESSMENT; RISK ASSESSMENT; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84954349692     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
2. Curran KJ, Riviere I, Silverman LB, et al. Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL [ASH abstract 2533]. Blood. 2015;126(23)(suppl).
3. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
4. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
5. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
6. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
7. Park JH, Riviere I, Wang X, et al. Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL [ASH abstract 682]. Blood. 2015;126(23)(suppl).
8. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.